Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Biogen (BIIB) to $157 from $192 and keeps an Equal Weight rating on the shares. The firm lowers estimates as initial 2025 guidance came in light and Skyclarys was “flat again,” the analyst tells investors. Looking ahead, the Leqembi Alzheimer’s launch “remains the key growth driver,” the analyst added in a post-earnings note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen (BIIB) Q4 Results Make Analysts Feel Poorly About its Prospects
- Biogen price target lowered to $241 from $300 at H.C. Wainwright
- Cautious Outlook on Biogen Amid Declining MS Revenues and Uncertain Growth Prospects
- Biogen price target lowered to $265 from $298 at Canaccord
- Biogen price target lowered to $140 from $165 at Wells Fargo